Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

29 Jan 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Pancreatic and Hepatic Oncology Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30696953
DOI: 10.1038/s41388-018-0650-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancerPMID 30696953Read ↗

TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancerSemantic proximity Read ↗

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor ResistanceSemantic proximity Read ↗

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Semantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancerSemantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilitiesSemantic proximity Read ↗

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySemantic proximity Read ↗

Common corruption of the mTOR signaling network in human tumorsSemantic proximity Read ↗

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapySemantic proximity Read ↗

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.